We are analyzing https://link.springer.com/article/10.1186/s12967-016-0905-x.

Title:
Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer | Journal of Translational Medicine
Description:
Identifying immune markers in blood that are informative for breast cancer patient survival would not only be useful for prognosis but might also provide mechanistic insights into processes facilitating survival. We phenotyped circulating plasmacytoid dendritic cells (pDCs), myeloid-derived suppressor cells (MDSCs) and regulatory T-cells in relation to T-cell responses to Her-2 in vitro in 75 untreated breast cancer patients 28–87 years of age at diagnosis. Patients with later stage tumors had lower levels of circulating pDCs (p = 0.008). There was a positive association between 5-year survival and higher than median levels of circulating pDCs (p = 0.03). We confirmed that 5-year survival correlated with CD8+ but not CD4+ T-cell responsiveness to Her-2 peptides in this cohort of younger and older patients (p = 0.04). Including pDCs in the analysis of previously-established parameters revealed that patients who had a CD8+ T-cell response to Her-2 together with a low ratio of MDSCs:pDCs had 100 % 5-year survival. High levels of pDCs and the presence of a CD8+ T-cell response to Her-2 were independent positive survival indicators according to multivariate Cox analysis. Our new results suggest that circulating pDCs could be a positive prognostic indicator in breast cancer patients of all ages, together with the previously established CD8+ T-cell reactivity to Her-2 antigens in older patients only. These two prognostic indicators were independent and emphasize the important role of immunity in ensuring breast cancer patient survival, even in those not undergoing immunotherapy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

patients, tcell, cells, pdcs, survival, pubmed, cancer, article, levels, responses, response, dcs, google, scholar, dendritic, cas, high, low, breast, analysis, tumor, circulating, tcells, data, plasmacytoid, mdcs, fig, ratio, study, blood, stage, cell, observed, central, nonmetastatic, mdscs, mdsc, immunol, higher, melanoma, shown, additional, impact, subsets, compared, ratios, prognostic, immunosuppressive, file, suppressor,

Topics {✒️}

fsc-area-versus-fsc-height/width plot cross-prime cd8+ t-cells tumour-specific t-cell responses taa-specific t-cell responses taa-specific cd8+ t-cells bd-lsr-ii flow cytometer myeloid-derived suppressor cells natural interferon-producing cells jithendra kini bailur kaplan–meier analysis showed cd8+ t-cell cytotoxicity 2-reactive t-cells assayed cd8{alpha}+ dendritic cells cd8+ t-cell responses cd8+ t-cell responders cd8+ t-cell stimulation cd8+ t-cell response peripheral t-cell reactivity cd4+ t-cell responses foxp3+ cd4+ t-cells foxp3+/cd4+ t-cells cd4+ t-cell responsiveness article download pdf kaplan–meir analysis showed induce t-cell immunity cd4+ t-cell response cd8-peridinin-chlorophyll protein vitro t-cell responses previously-established parameters revealed plasmacytoid dendritic cells multivariate cox analysis foxp3+ natural regulatory kaplan–meier analysis myeloid suppressor cells high-dose weekly schedule hla-dr-percp-cy5 tumor antigen-loaded pdcs myeloid dendritic cells dendritic cell vaccines full access 2-specific t-cells specific t-cells t-cell responses impair t-cell patients clinico-pathological parameters t-cell response pdcs produce interferon-α regulatory t-cells memory th1 polarization cell-based immunotherapy

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer
         description:Identifying immune markers in blood that are informative for breast cancer patient survival would not only be useful for prognosis but might also provide mechanistic insights into processes facilitating survival. We phenotyped circulating plasmacytoid dendritic cells (pDCs), myeloid-derived suppressor cells (MDSCs) and regulatory T-cells in relation to T-cell responses to Her-2 in vitro in 75 untreated breast cancer patients 28–87 years of age at diagnosis. Patients with later stage tumors had lower levels of circulating pDCs (p = 0.008). There was a positive association between 5-year survival and higher than median levels of circulating pDCs (p = 0.03). We confirmed that 5-year survival correlated with CD8+ but not CD4+ T-cell responsiveness to Her-2 peptides in this cohort of younger and older patients (p = 0.04). Including pDCs in the analysis of previously-established parameters revealed that patients who had a CD8+ T-cell response to Her-2 together with a low ratio of MDSCs:pDCs had 100 % 5-year survival. High levels of pDCs and the presence of a CD8+ T-cell response to Her-2 were independent positive survival indicators according to multivariate Cox analysis. Our new results suggest that circulating pDCs could be a positive prognostic indicator in breast cancer patients of all ages, together with the previously established CD8+ T-cell reactivity to Her-2 antigens in older patients only. These two prognostic indicators were independent and emphasize the important role of immunity in ensuring breast cancer patient survival, even in those not undergoing immunotherapy.
         datePublished:2016-05-28T00:00:00Z
         dateModified:2016-05-28T00:00:00Z
         pageStart:1
         pageEnd:10
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12967-016-0905-x
         keywords:
            Breast cancer
            T-cells
            Plasmacytoid dendritic cells
            Myeloid derived suppressor cells
            Regulatory T-cells
            Her-2
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-016-0905-x/MediaObjects/12967_2016_905_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-016-0905-x/MediaObjects/12967_2016_905_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-016-0905-x/MediaObjects/12967_2016_905_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-016-0905-x/MediaObjects/12967_2016_905_Fig4_HTML.gif
         isPartOf:
            name:Journal of Translational Medicine
            issn:
               1479-5876
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jithendra Kini Bailur
               affiliation:
                     name:University Hospital Tübingen
                     address:
                        name:Department of Internal Medicine II, Centre for Medical Research, University Hospital Tübingen, Tübingen, Germany
                        type:PostalAddress
                     type:Organization
                     name:Yale University School of Medicine
                     address:
                        name:Yale Cancer Center, Yale University School of Medicine, New Haven, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Brigitte Gueckel
               affiliation:
                     name:University Hospital Tübingen
                     address:
                        name:Radiology Clinic, Diagnostic and Interventional Radiology, University Hospital Tübingen, Tübingen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Graham Pawelec
               affiliation:
                     name:University Hospital Tübingen
                     address:
                        name:Department of Internal Medicine II, Centre for Medical Research, University Hospital Tübingen, Tübingen, Germany
                        type:PostalAddress
                     type:Organization
                     name:Nottingham Trent University
                     address:
                        name:School of Science and Technology, College of Arts and Science, Nottingham Trent University, Nottingham, UK
                        type:PostalAddress
                     type:Organization
                     name:King’s College London
                     address:
                        name:Division of Cancer Studies, Faculty of Life Sciences and Medicine, King’s College London, London, UK
                        type:PostalAddress
                     type:Organization
                     name:University of Manchester
                     address:
                        name:Institute of Cancer Sciences, University of Manchester, Manchester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer
      description:Identifying immune markers in blood that are informative for breast cancer patient survival would not only be useful for prognosis but might also provide mechanistic insights into processes facilitating survival. We phenotyped circulating plasmacytoid dendritic cells (pDCs), myeloid-derived suppressor cells (MDSCs) and regulatory T-cells in relation to T-cell responses to Her-2 in vitro in 75 untreated breast cancer patients 28–87 years of age at diagnosis. Patients with later stage tumors had lower levels of circulating pDCs (p = 0.008). There was a positive association between 5-year survival and higher than median levels of circulating pDCs (p = 0.03). We confirmed that 5-year survival correlated with CD8+ but not CD4+ T-cell responsiveness to Her-2 peptides in this cohort of younger and older patients (p = 0.04). Including pDCs in the analysis of previously-established parameters revealed that patients who had a CD8+ T-cell response to Her-2 together with a low ratio of MDSCs:pDCs had 100 % 5-year survival. High levels of pDCs and the presence of a CD8+ T-cell response to Her-2 were independent positive survival indicators according to multivariate Cox analysis. Our new results suggest that circulating pDCs could be a positive prognostic indicator in breast cancer patients of all ages, together with the previously established CD8+ T-cell reactivity to Her-2 antigens in older patients only. These two prognostic indicators were independent and emphasize the important role of immunity in ensuring breast cancer patient survival, even in those not undergoing immunotherapy.
      datePublished:2016-05-28T00:00:00Z
      dateModified:2016-05-28T00:00:00Z
      pageStart:1
      pageEnd:10
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12967-016-0905-x
      keywords:
         Breast cancer
         T-cells
         Plasmacytoid dendritic cells
         Myeloid derived suppressor cells
         Regulatory T-cells
         Her-2
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-016-0905-x/MediaObjects/12967_2016_905_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-016-0905-x/MediaObjects/12967_2016_905_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-016-0905-x/MediaObjects/12967_2016_905_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-016-0905-x/MediaObjects/12967_2016_905_Fig4_HTML.gif
      isPartOf:
         name:Journal of Translational Medicine
         issn:
            1479-5876
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jithendra Kini Bailur
            affiliation:
                  name:University Hospital Tübingen
                  address:
                     name:Department of Internal Medicine II, Centre for Medical Research, University Hospital Tübingen, Tübingen, Germany
                     type:PostalAddress
                  type:Organization
                  name:Yale University School of Medicine
                  address:
                     name:Yale Cancer Center, Yale University School of Medicine, New Haven, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Brigitte Gueckel
            affiliation:
                  name:University Hospital Tübingen
                  address:
                     name:Radiology Clinic, Diagnostic and Interventional Radiology, University Hospital Tübingen, Tübingen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Graham Pawelec
            affiliation:
                  name:University Hospital Tübingen
                  address:
                     name:Department of Internal Medicine II, Centre for Medical Research, University Hospital Tübingen, Tübingen, Germany
                     type:PostalAddress
                  type:Organization
                  name:Nottingham Trent University
                  address:
                     name:School of Science and Technology, College of Arts and Science, Nottingham Trent University, Nottingham, UK
                     type:PostalAddress
                  type:Organization
                  name:King’s College London
                  address:
                     name:Division of Cancer Studies, Faculty of Life Sciences and Medicine, King’s College London, London, UK
                     type:PostalAddress
                  type:Organization
                  name:University of Manchester
                  address:
                     name:Institute of Cancer Sciences, University of Manchester, Manchester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Translational Medicine
      issn:
         1479-5876
      volumeNumber:14
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University Hospital Tübingen
      address:
         name:Department of Internal Medicine II, Centre for Medical Research, University Hospital Tübingen, Tübingen, Germany
         type:PostalAddress
      name:Yale University School of Medicine
      address:
         name:Yale Cancer Center, Yale University School of Medicine, New Haven, USA
         type:PostalAddress
      name:University Hospital Tübingen
      address:
         name:Radiology Clinic, Diagnostic and Interventional Radiology, University Hospital Tübingen, Tübingen, Germany
         type:PostalAddress
      name:University Hospital Tübingen
      address:
         name:Department of Internal Medicine II, Centre for Medical Research, University Hospital Tübingen, Tübingen, Germany
         type:PostalAddress
      name:Nottingham Trent University
      address:
         name:School of Science and Technology, College of Arts and Science, Nottingham Trent University, Nottingham, UK
         type:PostalAddress
      name:King’s College London
      address:
         name:Division of Cancer Studies, Faculty of Life Sciences and Medicine, King’s College London, London, UK
         type:PostalAddress
      name:University of Manchester
      address:
         name:Institute of Cancer Sciences, University of Manchester, Manchester, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jithendra Kini Bailur
      affiliation:
            name:University Hospital Tübingen
            address:
               name:Department of Internal Medicine II, Centre for Medical Research, University Hospital Tübingen, Tübingen, Germany
               type:PostalAddress
            type:Organization
            name:Yale University School of Medicine
            address:
               name:Yale Cancer Center, Yale University School of Medicine, New Haven, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Brigitte Gueckel
      affiliation:
            name:University Hospital Tübingen
            address:
               name:Radiology Clinic, Diagnostic and Interventional Radiology, University Hospital Tübingen, Tübingen, Germany
               type:PostalAddress
            type:Organization
      name:Graham Pawelec
      affiliation:
            name:University Hospital Tübingen
            address:
               name:Department of Internal Medicine II, Centre for Medical Research, University Hospital Tübingen, Tübingen, Germany
               type:PostalAddress
            type:Organization
            name:Nottingham Trent University
            address:
               name:School of Science and Technology, College of Arts and Science, Nottingham Trent University, Nottingham, UK
               type:PostalAddress
            type:Organization
            name:King’s College London
            address:
               name:Division of Cancer Studies, Faculty of Life Sciences and Medicine, King’s College London, London, UK
               type:PostalAddress
            type:Organization
            name:University of Manchester
            address:
               name:Institute of Cancer Sciences, University of Manchester, Manchester, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Internal Medicine II, Centre for Medical Research, University Hospital Tübingen, Tübingen, Germany
      name:Yale Cancer Center, Yale University School of Medicine, New Haven, USA
      name:Radiology Clinic, Diagnostic and Interventional Radiology, University Hospital Tübingen, Tübingen, Germany
      name:Department of Internal Medicine II, Centre for Medical Research, University Hospital Tübingen, Tübingen, Germany
      name:School of Science and Technology, College of Arts and Science, Nottingham Trent University, Nottingham, UK
      name:Division of Cancer Studies, Faculty of Life Sciences and Medicine, King’s College London, London, UK
      name:Institute of Cancer Sciences, University of Manchester, Manchester, UK

External Links {🔗}(172)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

4.57s.

LINK . SPRINGER . COM {}